About us Contacts Drug interactions: 390 212
Drug search by name

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and Zytiga

Determining the interaction of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets and Zytiga and the possibility of their joint administration.

Check result:
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets <> Zytiga
Relevance: 28.11.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Abiraterone may increase the blood levels of dasabuvir, one of the components of your hepatitis C medication. In some cases, this may increase the risk of side effects such as irregular heart rhythm and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of dasabuvir, which is primarily metabolized by the isoenzyme. In 11 study subjects, the potent CYP450 2C8 inhibitor gemfibrozil given at 600 mg twice daily increased single-dose dasabuvir peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 2- and 11-fold, respectively. The risk of ALT elevations and QT prolongation may be increased.

MANAGEMENT: Caution is advised if dasabuvir is prescribed in combination with CYP450 2C8 inhibitors. Patients should be monitored for development of hepatotoxicity (i.e., ALT elevations) and QT interval prolongation.

References
  • "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir)." AbbVie US LLC, North Chicago, IL.
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets

Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir

Brand name: Viekira XR, Viekira Pak

Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir

Zytiga

Generic Name: abiraterone

Brand name: Yonsa, Zytiga

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.